Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel

Shintaro Narita, Takahiro Kimura, Shingo Hatakeyama, Kenichi Hata, Takafumi Yanagisawa, Shinya Maita, Shuji Chiba, Hiromi Sato, Soki Kashima, Atsushi Koizumi, Ryohei Yamamoto, Koichiro Takayama, Katsumi Okane, Toshiya Ishida, Yohei Horikawa, Teruaki Kumazawa, Jiro Shimoda, Takehiro Suzuki, Chikara Ohyama, Shin Egawa, Tomonori Habuchi

Open source

DOI: 10.1007/s10147-022-02203-y
Published: 2022-06-24
Container: International Journal of Clinical Oncology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10147-022-02203-y,
  title = {Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel},
  author = {Shintaro Narita and Takahiro Kimura and Shingo Hatakeyama and Kenichi Hata and Takafumi Yanagisawa and Shinya Maita and Shuji Chiba and Hiromi Sato and Soki Kashima and Atsushi Koizumi and Ryohei Yamamoto and Koichiro Takayama and Katsumi Okane and Toshiya Ishida and Yohei Horikawa and Teruaki Kumazawa and Jiro Shimoda and Takehiro Suzuki and Chikara Ohyama and Shin Egawa and Tomonori Habuchi},
  year = {2022},
  journal = {International Journal of Clinical Oncology},
  doi = {10.1007/s10147-022-02203-y},
  url = {https://doi.org/10.1007/s10147-022-02203-y}
}

RIS

TY  - JOUR
TI  - Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel
AU  - Shintaro Narita
AU  - Takahiro Kimura
AU  - Shingo Hatakeyama
AU  - Kenichi Hata
AU  - Takafumi Yanagisawa
AU  - Shinya Maita
AU  - Shuji Chiba
AU  - Hiromi Sato
AU  - Soki Kashima
AU  - Atsushi Koizumi
AU  - Ryohei Yamamoto
AU  - Koichiro Takayama
AU  - Katsumi Okane
AU  - Toshiya Ishida
AU  - Yohei Horikawa
AU  - Teruaki Kumazawa
AU  - Jiro Shimoda
AU  - Takehiro Suzuki
AU  - Chikara Ohyama
AU  - Shin Egawa
AU  - Tomonori Habuchi
PY  - 2022
JO  - International Journal of Clinical Oncology
DO  - 10.1007/s10147-022-02203-y
UR  - https://doi.org/10.1007/s10147-022-02203-y
ER  -

APA

Narita, S., Kimura, T., Hatakeyama, S., Hata, K., Yanagisawa, T., Maita, S., Chiba, S., Sato, H., Kashima, S., Koizumi, A., Yamamoto, R., Takayama, K., Okane, K., Ishida, T., Horikawa, Y., Kumazawa, T., Shimoda, J., Suzuki, T., Ohyama, C., Egawa, S., & Habuchi, T. (2022). Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-022-02203-y

Source records

crossref · retrieved 2026-09-27T07:05:54.934Z